New Key Statistics Module, Z-Score and F-Score
NAS:GRCE Key Ratios
| Market Cap $ M | 48.07 |
| Enterprise Value $ M | 34.42 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.77 |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -1.17 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | 34.30 |
| 5-y EBITDA Growth Rate % | 27.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -3.32 |
| EV-to-EBITDA | -3.32 |
| PEG | -- |
| Shares Outstanding M | 21.04 |
| Net Margin (%) | -- |
| Operating Margin % | -- |
| Pre-tax Margin (%) | -- |
| Quick Ratio | 11.47 |
| Current Ratio | 11.47 |
| ROA % (ttm) | -31.44 |
| ROE % (ttm) | -33.33 |
| ROIC % (ttm) | -20.54 |
| Dividend Yield % | -- |
| Altman Z-Score | -- |
GRCE Number of Guru Trades
GRCE Volume of Guru Trades
Gurus Latest Trades with NAS:GRCE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:GRCE is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Grace Therapeutics Inc Insider Transactions
No Available Data
News about NAS:GRCE
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers